Category - Developments

Developments

Innate Pharma announces positive outcomes from TELLOMAK Phase 2 Study

Innate Pharma S.A. (Euronext Paris:IPH; Nasdaq:IPHA) presented positive results from its Phase 2 TELLOMAK study with lacutamab in mycosis fungoides at the ASCO 2024 Annual Meeting in Chicago. The company reported that...

June 5, 2024

Developments

Trinity Biotech unveils new microsite to highlight distinctive technology and AI-driven platform

Trinity Biotech (NASDAQ: TRIB) has announced the launch of its continuous glucose monitoring (CGM) microsite to provide insights into the development of its next-generation CGM biosensor technology and AI-driven health...

June 3, 2024

Developments

Verve Therapeutics appoints Troy Lister as CSO

Verve Therapeutics (NASDAQ:VERVE) has appointed Troy Lister, Ph.D., as CSO, effective June 21, 2024, succeeding Andrew Bellinger, M.D., Ph.D., who will serve in an advisory capacity. Currently, Dr. Lister serves as...

June 3, 2024

Developments

OneMedNet inks MSA with top-10 global medtech company

OneMedNet (NASDAQ:ONMD) has entered into a non-exclusive three-year MSA with an undisclosed U.S.-based medical technology company that affects more than 150 million patients worldwide annually. OneMedNet will utilize...

May 30, 2024

Developments

Lucy Therapeutics secures new funding to accelerate innovative Alzheimer’s and Parkinson’s Treatments

Closely-held Lucy Therapeutics (LucyTX) raised $12.5 million in additional funding to further the company’s research programs for Alzheimer’s and Parkinson’s diseases and continue its development of a novel drug target...

May 29, 2024

Developments

BerGenBio announces NCI clinical collaboration with UT Health San Antonio and Swedish Orphan Biovitrum AV

BerGenBio ASA (OSE: BGBIO) has announced that it has entered into a clinical trial agreement with the Mays Cancer Center at UT Health San Antonio and Swedish Orphan Biovitrum AV to study BerGenBio’s selective AXL...

May 29, 2024

Developments

OneMedNet reports greater than five-fold expansion of iRWD network and platform; posts new investor presentation

OneMedNet’s (Nasdaq:ONMD) stock rallied over 208% on more than 420 times average trading volumes today after reporting a greater than five-fold expansion of its proprietary iRWD network and platform through a series of...

May 23, 2024

Developments

Elixir Medical reports positive data from stress system to treat calcified lesions trial

Closely-held Elixir Medical has announced positive results from its PINNACLE I clinical trial evaluating the safety and effectiveness of its novel LithiX Hertz Contact Lithotripsy (IVL) System that uses stress to treat...

May 17, 2024

Developments

Takeda’s dengue vaccine receives WHO prequalification

Takeda (TSE: 4502/NYSE: TAK) TAK-003, a new dengue vaccine, has obtained WHO prequalification. WHO has also recommended TAK-003 for children aged six to 16 in regions that are at risk of the mosquito-borne viral disease...

May 16, 2024

Developments

Profound Medical receives FDA 510(k) clearance for ‘Contouring Assistant’ AI module enabling creation of automated TULSA treatment plan

Profound Medical (NASDAQ:PROF; TSX:PRN) announced that it has received FDA 510(k) clearance for its second TULSA-AI module, Contouring Assistant, a machine learning-based prostate segmentation tool, for use in...

May 14, 2024

Category - Developments

Innate Pharma announces positive outcomes from TELLOMAK Phase 2 Study

Trinity Biotech unveils new microsite to highlight distinctive technology and AI-driven platform

Verve Therapeutics appoints Troy Lister as CSO

OneMedNet inks MSA with top-10 global medtech company

Lucy Therapeutics secures new funding to accelerate innovative Alzheimer’s and Parkinson’s Treatments

BerGenBio announces NCI clinical collaboration with UT Health San Antonio and Swedish Orphan Biovitrum AV

OneMedNet reports greater than five-fold expansion of iRWD network and platform; posts new investor presentation

Elixir Medical reports positive data from stress system to treat calcified lesions trial

Takeda’s dengue vaccine receives WHO prequalification

Profound Medical receives FDA 510(k) clearance for ‘Contouring Assistant’ AI module enabling creation of automated TULSA treatment plan

General

More